University Hospital, Gentofte, Copenhagen: Diabetes Mellitus trials

The registry lists 27 Diabetes Mellitus studies with University Hospital, Gentofte, Copenhagen as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 3Phase 3 1Phase 4 1No phase 23(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 DiabetesCompletedNCT00321321Phase 2Results posted
• Neuronostatin - a Glucagonotropic Agent in Humans?CompletedNCT06143267Not applicable
• The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 DiabetesCompletedNCT06137586Not applicable
• The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 DiabetesCompletedNCT04228484Not applicable
• The Role of Pregnancy-induced Gallbladder Dysmotility in the Pathophysiology of Gestational Diabetes MellitusCompletedNCT04108065
• Effect of GIP After a Meal in Patients With Type 2 DiabetesCompletedNCT03702660Not applicable
• GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food IntakeCompletedNCT03526289Not applicable
• Hypoglycaemia and Cardiac Arrhythmias in Type 2 DiabetesCompletedNCT03150030
• The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without SulphonylureaCompletedNCT03081676Not applicable
• Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 DiabetesCompletedNCT03044860Not applicable
• Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 DiabetesCompletedNCT02669524Not applicable
• Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care SectorCompletedNCT02586545Not applicable
• Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon ClearanceCompletedNCT02475421Not applicable
• Life Without DiabetesCompletedNCT02212665Not applicable
• Correlation Between Plasma- and Endothelial DPP-4 ActivityCompletedNCT02192853Phase 4
• Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose InfusionCompletedNCT02010827
• The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)CompletedNCT01610934Phase 2/3
• The Effect of GLP-1 on the Inhibition of Glucagon SecretionCompletedNCT01507597Not applicable
• Pathophysiological Implications of the Incretin Hormones in Patients With Liver Disease With and Without DiabetesCompletedNCT01492283
• Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)CompletedNCT01342939
• Study of Postprandial Incretin Response in Women With Gestational DiabetesCompletedNCT01274052
• Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?CompletedNCT01048268Phase 1/2
• Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes MellitusCompletedNCT00923962Not applicable
• The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 DiabetesCompletedNCT00732602Not applicable
• Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 DiabetesStatus unknownNCT00704795
• Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes MellitusStatus unknownNCT00655603Not applicable
• The Incretin Effect in Patients With Chronic PancreatitisCompletedNCT00638573